

Severe Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19: A Regional Factor

Jussara A. Oliveira Baggio,¹ Ana Luiza Exel,² Ana Carolina do Nascimento Calles,² Vinicius Minatel²

Universidade Federal de Alagoas,¹ Arapiraca, AL - Brazil

Centro Universitário Tiradentes,² Maceió, AL - Brazil

Short Editorial related to the article: Prevalence and Associated Factors of SARS by Covid-19 in Adults and Aged People with Chronic Cardiovascular Disease

The COVID-19 (Coronavirus disease-19), a disease caused by the SARS-CoV-2, was identified in China at the end of 2019 and announced as a pandemic by the World Health Organization (WHO) in March 2020, with more than 20 million cases confirmed in Brazil, and more than 583 thousand deaths from complications of the disease, by the end of epidemiological week 35, on September 4, 2021.¹⁻³ According to the WHO, Brazil is the third country in number of cases, with the USA on the top of the list, followed by India,¹⁻³ which is also considered an emerging country with problems similar to those faced by the Brazilian population.

Symptoms of the SARS-CoV-2 infection may vary from a flu-like syndrome, with mild symptoms and signs like fever, cough, nasal congestion and fatigue, to acute respiratory distress syndrome (ARDS), with symptoms including dyspnea, O₂ saturation \leq 93%, respiratory rate \geq 30 breaths per minute, partial pressure of oxygen (PaO₂)/fraction of inspired oxygen (FiO₂) < 300, lymphopenia, and alveolar edema.^{4,5} Nearly 1,775,816 cases of ARDS secondary to COVID-19 were recorded in Brazil and 32.2% of the cases progressed to death.⁶ Of the 342,636 deaths for ARDS due to COVID-19 recorded up to the epidemiological week 36 in 2021, 59.5% had at least one comorbidity, with heart diseases, cerebrovascular diseases, systemic arterial hypertension and diabetes mellitus (DM) as the most common ones.^{6,7}

Considering the high prevalence of cardiovascular diseases (CVDs), especially in the elderly, and its association with more severe cases of the disease, Paiva et al.⁸ aimed at describing the prevalence of ARDS due to COVID-19 and evaluating the factors associated with this condition in adults and elderly with chronic CVD in Brazil up to the 30th epidemiological week in 2020. The authors used data from the epidemiological surveillance system on influenza (*Sistema de Informação de Vigilância Epidemiológica da Gripe, SIVEP-Gripe*) and included individuals with CVDs, aged over 18 years old, hospitalized for ARDS. In their study, 116,343 patients were included, 61.9% of them received a diagnosis of

ARDS due to COVID-19. The authors found clinical features, signs and symptoms that were similar to those described in the literature.⁹ Factors associated with ARDS due to COVID-19 were fever, cough, intensive care unit admission, use of invasive and non-invasive ventilation, and nosocomial infection. The results indicated a higher prevalence of ARDS in individuals aged over 60 years from the southeast of Brazil.

The results of Paiva et al.⁸ reflect what has already been pointed out in previous studies.¹⁰ The main contribution of the data on the prevalence of ARDS by COVID-19 analyzed by each variable. The authors found that most cases of ARDS in the north and northeast regions of Brazil were caused by COVID-19, which differed from the cases in the south of the country, where 39.9% of the cases were caused by COVID-19. These data indicate that the prevalence of COVID-19-related ARDS has a regional factor, and reflect the difference in the access to healthcare and social inequalities among the regions. A study published by Baggio et al.,¹¹ in Alagoas, showed a high incidence of COVID-19 in the cities with the highest human development indexes, as well as in those with high social vulnerability. However, the highest mortality rates were found in the poorest cities. The highest prevalence of comorbidities was observed in patients hospitalized for COVID-19, which explain in part the highest risk of death in this region.^{12,13} Besides, one should consider the morbidity profile, healthcare infrastructure (number of beds, trained professionals), and access to diagnostic tests and intensive therapy with qualified and safe processes by the patients.

The inclusion of data about the presence of other comorbidities, in addition to CVDs, like physical activity level and clinical follow-up for CVDs, would aid to improve the analysis conducted by the authors. Also, the inclusion of other comorbidities and physical activity level to the multivariate analysis would allow the establishment of survival and mortality curves associated to other comorbidities, including DM, obesity, sedentary lifestyle, among other common conditions that play an important role in the development of severe cases of COVID-19.

Keywords

Cardiovascular Diseases; COVID-19; Severe Acute Respiratory Syndrome.

Mailing Address: Jussara A. Oliveira Baggio •

Avenida Manoel Severino Barbosa, s/n. Postal Code 57309-005, Bairro

Bom Sucesso, Arapiraca, AL - Brazil

E-mail: jussarabaggio@gmail.com

DOI: <https://doi.org/10.36660/abc.20210803>

References

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032.
2. World Health Organization. Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV) [Internet]. Geneva: WHO; 2020 Jan 30 [cited 2021 Oct 01]. Available from: [https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)).
3. Secretária de Vigilância em Saúde. Boletim Epidemiológico Especial: Semana Epidemiológica 35 - 29/8 a 4/9/2021 [Internet]. Brasília: Ministério da Saúde; c2021 [cited 2021 Oct 02]. Available from: <https://www.gov.br/saude/pt-br/assuntos/boletins-epidemiologicos/numeros-recentes>.
4. Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive Care Management of Coronavirus Disease 2019 (COVID-19): Challenges and Recommendations. *Lancet Respir Med*. 2020;8(5):506-17. doi: 10.1016/S2213-2600(20)30161-2.
5. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and Multi-Organ Injuries in the Treatment of COVID-19. *Lancet*. 2020;395(10228):e52. doi: 10.1016/S0140-6736(20)30558-4.
6. Secretária de Vigilância em Saúde. Boletim Epidemiológico Especial: Semana Epidemiológica 36 - 5/9 a 11/9/2021 [Internet]. Brasília: Ministério da Saúde; c2021 [cited 2021 Oct 02]. Available from: <https://www.gov.br/saude/pt-br/assuntos/boletins-epidemiologicos/numeros-recentes>.
7. Li J, He X, Yuan Y, Zhang W, Li X, Zhang Y, et al. Meta-Analysis Investigating the Relationship Between Clinical Features, Outcomes, and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pneumonia. *Am J Infect Control*. 2021;49(1):82-9. doi: 10.1016/j.ajic.2020.06.008.
8. Paiva KM, Hillesheim D, Rech CR, Delevatti RS, Brown RVS, Gonzáles AI, et al. Prevalence and Associated Factors of SARS by Covid-19 in Adults and Aged People with Chronic Cardiovascular Disease. *Arq Bras Cardiol*. 2021; 117(5):968-975.
9. Santos LG, Baggio JAO, Leal TC, Costa FA, Fernandes TRMO, Silva RVD, et al. Prevalence of Systemic Arterial Hypertension and Diabetes Mellitus in Individuals with COVID-19: A Retrospective Study of Deaths in Pernambuco, Brazil. *Arq Bras Cardiol*. 2021;117(2):416-22. doi: 10.36660/abc.20200885.
10. Tavares CAM, Avelino-Silva TJ, Benard C, Cardozo FAM, Fernandes JR, Girardi ACC, et al. ACE2 Expression and Risk Factors for COVID-19 Severity in Patients with Advanced Age. *Arq Bras Cardiol*. 2020;115(4):701-7. doi: 10.36660/abc.20200487.
11. Baggio JAO, Machado MF, Carmo RFD, Armstrong ADC, Santos ADD, Souza CDF. COVID-19 in Brazil: Spatial Risk, Social Vulnerability, Human Development, Clinical Manifestations and Predictors of Mortality - A Retrospective study with Data from 59 695 Individuals. *Epidemiol Infect*. 2021;149:e100. doi: 10.1017/S0950268821000935.
12. Andrade CLT, Pereira CCA, Martins M, Lima SML, Portela MC. COVID-19 Hospitalizations in Brazil's Unified Health System (SUS). *PLoS One*. 2020;15(12):e0243126. doi: 10.1371/journal.pone.0243126.
13. Baqui P, Bica I, Marra V, Ercole A, van der Schaar M. Ethnic and Regional Variations in Hospital Mortality from COVID-19 in Brazil: A Cross-Sectional Observational Study. *Lancet Glob Health*. 2020;8(8):1018-26. doi: 10.1016/S2214-109X(20)30285-0.

